Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of SANGINITA
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 33.51 | 33.82 | 35.90 | 33.41 | 29.16 | 53.04 | 56.95 | 61.34 | 61.54 | 49.85 | 45.91 | 44.10 | 43.47 |
| Expenses + | 32.40 | 33.24 | 34.69 | 31.98 | 27.94 | 52.94 | 55.67 | 60.08 | 60.38 | 48.87 | 45.11 | 43.77 | 45.22 |
| Operating Profit | 1.11 | 0.58 | 1.21 | 1.43 | 1.22 | 0.10 | 1.28 | 1.26 | 1.16 | 0.98 | 0.80 | 0.33 | -1.75 |
| OPM % | 3.31% | 1.71% | 3.37% | 4.28% | 4.18% | 0.19% | 2.25% | 2.05% | 1.88% | 1.97% | 1.74% | 0.75% | -4.03% |
| Other Income + | 0.05 | 0.11 | 0.07 | 0.08 | 0.25 | 0.04 | 0.04 | 0.13 | 0.08 | 0.01 | 0.37 | 0.01 | 0.00 |
| Interest | 0.63 | 0.68 | 0.66 | 0.62 | 0.66 | 0.68 | 0.64 | 0.63 | 0.58 | 0.59 | 0.53 | 0.47 | 0.49 |
| Depreciation | 0.14 | 0.14 | 0.15 | 0.16 | 0.20 | 0.24 | 0.26 | 0.47 | 0.48 | 0.47 | 0.54 | 0.56 | 0.55 |
| Profit before tax | 0.39 | -0.13 | 0.47 | 0.73 | 0.61 | -0.78 | 0.42 | 0.29 | 0.18 | -0.07 | 0.10 | -0.69 | -2.79 |
| Tax % | 23.08% | -30.77% | 25.53% | 26.03% | 26.23% | -24.36% | 26.19% | 24.14% | 27.78% | -14.29% | -10.00% | -1.45% | -0.36% |
| Net Profit + | 0.29 | -0.10 | 0.35 | 0.54 | 0.46 | -0.58 | 0.31 | 0.22 | 0.14 | -0.05 | 0.11 | -0.68 | -2.78 |
| EPS in Rs | 0.11 | -0.04 | 0.14 | 0.21 | 0.18 | -0.22 | 0.12 | 0.08 | 0.05 | -0.02 | 0.04 | -0.26 | -1.07 |
Financials of SANGINITA
Annual income statement trend
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 119 | 129 | 151 | 155 | 197 | 188 | 160 | 164 | 197 | 149 | 151 | 230 | 183 |
| Expenses + | 114 | 124 | 147 | 150 | 189 | 178 | 151 | 160 | 195 | 145 | 147 | 225 | 183 |
| Operating Profit | 5 | 4 | 5 | 5 | 8 | 9 | 8 | 4 | 3 | 3 | 4 | 5 | 0 |
| OPM % | 4% | 3% | 3% | 3% | 4% | 5% | 5% | 2% | 1% | 2% | 3% | 2% | 0% |
| Other Income + | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 3 | 2 | 2 |
| Depreciation | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 1 | 1 | 2 | 2 | 5 | 5 | 4 | 1 | 0 | 1 | 1 | 1 | -3 |
| Tax % | 35% | 32% | 32% | 34% | 33% | 28% | 25% | 25% | 24% | 23% | 27% | 25% | |
| Net Profit + | 1 | 1 | 1 | 1 | 3 | 4 | 3 | 1 | 0 | 0 | 1 | 1 | -3 |
| EPS in Rs | 0.68 | 0.81 | 0.87 | 0.43 | 1.33 | 1.52 | 1.30 | 0.29 | 0.14 | 0.16 | 0.30 | 0.24 | -1.31 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of SANGINITA
Capital structure and asset base
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 26 | 26 |
| Reserves | 6 | 7 | 8 | 11 | 14 | 18 | 21 | 22 | 22 | 23 | 24 | 30 | 30 |
| Borrowings + | 23 | 23 | 25 | 26 | 26 | 29 | 35 | 29 | 35 | 29 | 33 | 26 | 26 |
| Other Liabilities + | 7 | 12 | 2 | 7 | 3 | 7 | 5 | 2 | 5 | 11 | 12 | 20 | 20 |
| Total Liabilities | 44 | 50 | 44 | 60 | 61 | 72 | 78 | 70 | 79 | 80 | 86 | 102 | 102 |
| Fixed Assets + | 5 | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 8 | 15 | 14 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 40 | 46 | 40 | 57 | 57 | 67 | 74 | 66 | 75 | 75 | 78 | 87 | 88 |
| Total Assets | 44 | 50 | 44 | 60 | 61 | 72 | 78 | 70 | 79 | 80 | 86 | 102 | 102 |
Financials of SANGINITA
Operating, investing and financing cash movement
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 6 | 2 | 0 | -7 | 3 | 1 | -2 | 9 | -3 | 14 | -2 | 3 |
| Cash from Investing Activity + | -0 | 0 | -0 | -0 | -1 | -1 | -1 | -0 | -0 | -1 | -4 | -10 |
| Cash from Financing Activity + | -6 | -2 | -0 | 8 | -2 | 0 | 2 | -8 | 4 | -13 | 6 | 7 |
| Net Cash Flow | 0 | -0 | 0 | 0 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 |
| Free Cash Flow | 6 | 2 | 0 | -8 | 2 | -0 | -2 | 8 | -4 | 13 | -6 | -6 |
| CFO/OP | 121% | 64% | 16% | -139% | 57% | 25% | -1% | 249% | -100% | 454% | -55% | 74% |
Financials of SANGINITA
Working capital efficiency and return ratios
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 86 | 64 | 96 | 66 | 62 | 89 | 65 | 46 | 63 | 64 | 58 |
| Inventory Days | 48 | 41 | 30 | 29 | 29 | 39 | 50 | 51 | 46 | 70 | 76 | 49 |
| Days Payable | 14 | 32 | 2 | 15 | 3 | 8 | 7 | 2 | 8 | 25 | 27 | 22 |
| Cash Conversion Cycle | 98 | 95 | 93 | 109 | 92 | 93 | 132 | 114 | 84 | 107 | 112 | 85 |
| Working Capital Days | 99 | 34 | 33 | 58 | 52 | 60 | 78 | 78 | 72 | 81 | 86 | 67 |
| ROCE % | 12% | 11% | 11% | 10% | 14% | 14% | 11% | 5% | 4% | 4% | 5% | 4% |
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…